Categories: Top News

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET

Conference Call Information

To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at http://ir.macrogenics.com/events.com. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACT: Contacts:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com 

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com 

GlobeNewswire

GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Recent Posts

The opinion of the Supervisory Board of Enefit Green AS on the voluntary takeover bid made by Eesti Energia AS on 8 April 2025.

Hereby we publish the opinion of the Supervisory Board of Enefit Green AS on the…

4 hours ago

Bitcoin ‘breaking out’ as it retakes $87K after early April slump

Bitcoin is now more correlated with gold, which reached another all-time high, while the US…

15 hours ago

Bitcoin price surging on Sunday evening

If BTC can break through the resistance level of $86,000, it may target higher levels,…

15 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

19 hours ago

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

20 hours ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

20 hours ago

This website uses cookies.